Official Title
An Open-Label Treatment Use Protocol for Ibrutinib (PCI-32765) in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Brief Summary

The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma (MCL) with early access to an investigational medication called ibrutinib (PCI-32765) and to collect safety information about the drug.

Approved for marketing
Treatment IND/Protocol
Relapsed or Refractory Mantle Cell Lymphoma

Drug: Ibrutinib
Ibrutinib

Eligibility Criteria

Inclusion Criteria:

- Patients, 18 years of age and older, with Mantle Cell Lymphoma who have relapsed or refractory disease after prior therapy are eligible.

Exclusion Criteria:

- Patients eligible for enrollment in any other ongoing clinical study of ibrutinib are not eligible.

- Patients previously treated with ibrutinib are not eligible.

- Patients enrolled in another interventional clinical study with therapeutic intent are not eligible.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years
Countries
Brazil
Puerto Rico
United States
Locations

Phoenix, Arizona,

Duarte, California,

La Jolla, California,

Los Angeles, California,

Stanford, California,

Denver, Colorado,

Norwalk, Connecticut,

Stamford, Connecticut,

Washington, District of Columbia,

Brandon, Florida,

Miami Beach, Florida,

Ocala, Florida,

Orlando, Florida,

Palm Beach Gardens, Florida,

Atlanta, Georgia,

Chicago, Illinois,

Springfield, Illinois,

Goshen, Indiana,

Sioux City, Iowa,

Lexington, Kentucky,

Louisville, Kentucky,

Metairie, Louisiana,

Baltimore, Maryland,

Boston, Massachusetts,

Worcester, Massachusetts,

Ann Arbor, Michigan,

Detroit, Michigan,

Rochester, Minnesota,

Jefferson City, Missouri,

Saint Louis, Missouri,

Lincoln, Nebraska,

Omaha, Nebraska,

Reno, Nevada,

Hackensack, New Jersey,

New Hyde Park, New York,

New York, New York,

Syracuse, New York,

Durham, North Carolina,

Cleveland, Ohio,

Columbus, Ohio,

Hershey, Pennsylvania,

Philadelphia, Pennsylvania,

Pittsburgh, Pennsylvania,

Watertown, South Dakota,

Knoxville, Tennessee,

Nashville, Tennessee,

Austin, Texas,

Dallas, Texas,

Houston, Texas,

Lubbock, Texas,

Burlington, Vermont,

Charlottesville, Virginia,

Morgantown, West Virginia,

Madison, Wisconsin,

Janssen Biotech, Inc.
Pharmacyclics LLC.
EA Number
Keywords
Mantle Cell Lymphoma
Ibrutinib
MeSH Terms
Lymphoma
Lymphoma, Mantle-Cell